Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
21.20
+8.42 (65.88%)
At close: Mar 6, 2026, 4:00 PM EST
21.16
-0.04 (-0.19%)
After-hours: Mar 6, 2026, 7:58 PM EST
DAWN Employees
Day One Biopharmaceuticals had 178 employees as of December 31, 2025. The number of employees decreased by 3 or -1.66% compared to the previous year.
Employees
178
Change (1Y)
-3
Growth (1Y)
-1.66%
Revenue / Employee
$888,663
Profits / Employee
-$602,933
Market Cap
2.19B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,371 |
| Iovance Biotherapeutics | 975 |
| Adaptive Biotechnologies | 624 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Ocular Therapeutix | 325 |
| Immunome | 168 |
DAWN News
- 1 day ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - Newsfile Corp
- 1 day ago - Is there any upside left in DAWN stock as it soars 65%? - Invezz
- 1 day ago - Day One Shares Surge After $2.5B Servier Deal - Benzinga
- 1 day ago - Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion - Reuters
- 1 day ago - Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - GlobeNewsWire
- 2 days ago - Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth - Seeking Alpha
- 8 days ago - Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead - Seeking Alpha
- 10 days ago - Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript - Seeking Alpha